
What is claimed is:

1. A compound of Formula (**I**):



(**I**)

or a pharmaceutically acceptable salt thereof, wherein:

--- represents a single bond or a double bond;

L is CR^9R^{9a}, O, S, SO, or SO_2;

Cy^1 is selected from phenyl or a 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said phenyl or 5-6 membered heteroaryl of Cy^1 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{11};

R^1 and R^2 are independently selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$, $S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^1 and R^2 are optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$, $S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$;

provided neither R^1 nor R^2 are Cl, Br, I, CN, or OH when L is O or S;

alternatively, R^1 and R^2 together with the carbon atom to which they are attached are combined to form a C_{3-7} cycloalkyl group, wherein said cycloalkyl group is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{20};

Cy^3 is selected from phenyl, C_{3-7} cycloalkyl, a 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said phenyl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Cy^3 is optionally substituted with

1, 2, 3, or 4 groups independently selected from R^{13}, wherein a ring-forming nitrogen atom of said 5-10 membered heteroaryl group or a ring-forming nitrogen atom of said 4-10 membered heterocycloalkyl group is optionally oxidized;

R^4 is H, $C(=O)NR^{14a}R^{14b}$, $C(=O)R^{14a}$, $C(=O)OR^{14a}$, or C_{1-6} alkyl optionally substituted by 1, 2, or 3 substituents independently selected from halo, $NR^{14a}R^{14b}$, OR^{14a}, SR^{14a}, CN, $C(=O)R^{14a}$, $C(=O)NR^{14a}R^{14b}$, $C(=O)OR^{14a}$, $OC(=O)R^{14b}$, $OC(=O)NR^{14a}R^{14b}$, $NR^{14a}C(=O)R^{14b}$, $NR^{14a}C(=O)NR^{14a}R^{14b}$, $NR^{14a}C(=O)OR^{14b}$, $S(=O)R^{14a}$, $S(=O)NR^{14a}R^{14b}$, $S(=O)_2R^{14a}$, $NR^{14a}S(=O)_2R^{14b}$, and $S(=O)_2NR^{14a}R^{14b}$;

R^5 is selected from =O and =S when C---N is a single bond,

alternatively, when C---N is a double bond then R^5 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $NR^{15a}R^{15b}$, $-C(=O)NR^{15a}R^{15b}$, $-C(=O)OR^{15a}$, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, and 4-10 membered heterocycloalkyl of R^5 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R^{15};

R^6 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, and C_{1-6} haloalkyl, wherein said alkyl, alkenyl, and alkynyl of R^6 are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{16};

alternatively, R^6 is selected from C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^6 are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^7 is selected from H, halo, CN, OR^a, NR^cR^d, SR^b, $C(=O)NR^cR^d$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and a 4-7 membered heterocycloalkyl

group of R^7 are optionally substituted with 1, 2, or 3 groups independently selected from R^{17};

R^8 is selected from H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$, wherein said C_{1-3} alkyl of R^8 is optionally substituted with 1, 2, or 3 groups independently selected from R^{18};

R^9 and R^{9a} are independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^{11} is independently at each occurrence selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$, wherein said C_{1-3} alkyl is optionally substituted by OH;

R^{13} is independently at each occurrence selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{13} is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$;

R^{15} is independently at each occurrence selected from H, C_{1-6} alkyl, C_{3-7} cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, CN, OR^{a5}, SR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $OC(=O)R^{b5}$, $OC(=O)NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(=O)R^{b5}$, $NR^{c5}C(=O)NR^{c5}R^{d5}$, $NR^{c5}C(=O)OR^{a5}$, $S(=O)R^{b5}$, $S(=O)NR^{c5}R^{d5}$, $S(=O)_2R^{b5}$, $NR^{c5}S(=O)_2R^{b5}$, and $S(=O)_2NR^{c5}R^{d5}$, wherein said C_{1-6} alkyl, C_{3-7} cycloalkyl, 4-7 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR^{a5}, SR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $OC(=O)R^{b5}$, $OC(=O)NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(=O)R^{b5}$, $NR^{c5}C(=O)NR^{c5}R^{d5}$, $NR^{c5}C(=O)OR^{a5}$, $S(=O)R^{b5}$, $S(=O)NR^{c5}R^{d5}$, $S(=O)_2R^{b5}$, $NR^{c5}S(=O)_2R^{b5}$, $S(=O)_2NR^{c5}R^{d5}$, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl, and C_{3-7} cycloalkyl;

R^{14a} and R^{14b} are independently at each occurrence selected from H and C_{1-6} alkyl, wherein said C_{1-6} alkyl of R^{14a} and R^{14b} is optionally substituted with 1, 2, or 3 substituents selected from R^{20};

or R^{14a} and R^{14b} together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents selected from R^{20};

R^{15a} and R^{15b} are independently at each occurrence selected from H and C_{1-6} alkyl, wherein said C_{1-6} alkyl of R^{15a} and R^{15b} is optionally substituted with 1, 2, or 3 substituents selected from R^{20};

or R^{15a} and R^{15b} together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents selected from R^{20};

R^{16} is independently at each occurrence selected from halo, CN, OH, OR^{a6}, SR^{a6}, $C(=O)R^{b6}$, $C(=O)NR^{c6}R^{d6}$, $C(=O)OR^{a6}$, $OC(=O)R^{b6}$, $OC(=O)NR^{c6}R^{d6}$, $NR^{c6}R^{d6}$, $NR^{c6}C(=O)R^{b6}$, $NR^{c6}C(=O)NR^{c6}R^{d6}$, $NR^{c6}C(=O)OR^{a6}$, $S(=O)R^{b6}$, $S(=O)NR^{c6}R^{d6}$, $S(=O)_2R^{b6}$, $NR^{c6}S(=O)_2R^{b6}$ and $S(=O)_2NR^{c6}R^{d6}$, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^{16} are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^{17} and R^{18} are independently at each occurrence selected from halo, C_{1-4} alkyl, CN, OR^a, NR^cR^d, SR^b, $C(=O)NR^cR^d$, $C(=O)OR^a$, and $NR^cC(=O)R^a$;

R^a, R^c, and R^d are independently at each occurrence selected from H, C_{1-6} alkyl, $C(O)R^e$, $S(=O)_2R^f$, $C(=O)NR^gR^h$, and phenyl optionally substituted by C_{1-4} alkoxy;

R^b is at each occurrence C_{1-6} alkyl;

R^e is at each occurrence C_{1-4} alkyl optionally substituted by a group selected from phenyl, C_{1-4} alkoxy, amino, C_{1-4} alkylamino, and C_{2-8} dialkylamino;

R^f is C_{1-4} alkyl;

R^g and R^h are independenetly at each occurrence selected from H and C_{1-4} alkyl;

R^{a1}, R^{b1}, R^{c1} and R^{d1} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a1}, R^{b1}, R^{c1} and R^{d1} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a3}, R^{b3}, R^{c3} and R^{d3} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a3}, R^{b3}, R^{c3} and R^{d3} are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, OR^{a4}, SR^{a4}, $C(=O)R^{b4}$, $C(=O)NR^{c4}R^{d4}$, $C(=O)OR^{a4}$, $OC(=O)R^{b4}$, $OC(=O)NR^{c4}R^{d4}$, $NR^{c4}R^{d4}$, $NR^{c4}C(=O)R^{b4}$, $NR^{c4}C(=O)NR^{c4}R^{d4}$, $NR^{c4}C(=O)OR^{a4}$, $S(=O)R^{b4}$, $S(=O)NR^{c4}R^{d4}$, $S(=O)_2R^{b4}$, $NR^{c4}S(=O)_2R^{b4}$ and $S(=O)_2NR^{c4}R^{d4}$;

R^{a4}, R^{b4}, R^{c4} and R^{d4} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a4}, R^{b4}, R^{c4} and R^{d4} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a5}, R^{b5}, R^{c5} and R^{d5} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, 5-6 membered heterocycloalkyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a5}, R^{b5}, R^{c5} and R^{d5} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

or R^{c5} and R^{d5} together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};


R^{a6}, R^{c6} and R^{d6} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a6}, R^{c6} and R^{d6} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

alternatively, R^{c6} and R^{d6} together with the nitrogen atom to which they are attached form a 4-7 membered heterocycloalkyl group comprising carbon, nitrogen, and 0, 1, or 2 additional heteroatoms selected from N, O and S, wherein said 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{b6} is independently at each occurrence selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and 4-7 membered heterocycloalkyl group are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20}; and

R^{20} is at each occurrence independently selected from H, halo, OH, CN, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkyl-C(=O)-, C_{1-4} alkyl-C(=O)O-, C_{1-4} alkyl-OC(=O)-, HOC(=O)-, $H_2NC(=O)$-, C_{1-4} alkyl-NHC(=O)-, di(C_{1-4} alkyl)NC(=O)-, C_{1-4} alkyl-C(=O)NH-, C_{1-4} alkyl-O-C(=O)NH-, C_{1-4} alkyl-S(=O)-, $H_2NS(=O)$-, C_{1-4} alkyl-NHS(=O)-, di(C_{1-4} alkyl)NS(=O)-, C_{1-4} alkyl-$S(=O)_2$-, C_{1-4} alkyl-$S(=O)_2NH$-, $H_2NS(=O)_2$-, C_{1-4} alkyl-$NHS(=O)_2$-, and di(C_{1-4} alkyl)$NS(=O)_2$-.

2. A compound of claim 1 of Formula (**I**):



(**I**)

or a pharmaceutically acceptable salt thereof, wherein:

--- represents a single bond or a double bond;

L is CR^9R^{9a}, O, S, SO, or SO_2;

Cy^1 is selected from phenyl or a 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said phenyl or 5-6 membered heteroaryl of Cy^1 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{11};

R^1 and R^2 are independently selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$, $S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^1 and R^2 are optionally substituted with 1, 2, or 3 groups independently

selected from halo, CN, OH, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$, $S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$;

provided neither R^1 nor R^2 are Cl, Br, I, CN, or OH when L is O or S;

alternatively, R^1 and R^2 together with the carbon atom to which they are attached may be combined to form a C_{3-7} cycloalkyl group, wherein said cycloalkyl group is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{20};

Cy^3 is selected from phenyl, C_{3-7} cycloalkyl, a 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said phenyl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Cy^3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}, wherein a ring-forming nitrogen atom of said 5-10 membered heteroaryl group or a ring-forming nitrogen atom of said 4-10 membered heterocycloalkyl group is optionally oxidized;

R^4 is H or C_{1-6} alkyl;

R^5 is selected from =O and =S when C---N is a single bond,

alternatively, when C---N is a double bond then R^5 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $NR^{15a}R^{15b}$, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^5 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R^{15};

R^6 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said alkyl, alkenyl, and alkynyl of R^6 are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{16};

alternatively, R^6 is selected from C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10

membered heteroaryl, and 4-7 membered heterocycloalkyl of R^6 are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^7 is selected from H, halo, CN, OR^a, NR^cR^d, SR^b, $C(=O)NR^cR^d$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and a 4-7 membered heterocycloalkyl group of R^7 are optionally substituted with 1, 2, or 3 groups independently selected from R^{17};

R^8 is selected from H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$, wherein said C_{1-3} alkyl of R^8 is optionally substituted with 1, 2, or 3 groups independently selected from R^{18};

R^9 and R^{9a} are independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^{11} is independently at each occurrence selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^{13} is independently at each occurrence selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{13} is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$;

R^{15} is independently at each occurrence selected from H, halo, CN, OH, OR^{a5}, SR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $OC(=O)R^{b5}$, $OC(=O)NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(=O)R^{b5}$, $NR^{c5}C(=O)NR^{c5}R^{d5}$, $NR^{c5}C(=O)OR^{a5}$, $S(=O)R^{b5}$, $S(=O)NR^{c5}R^{d5}$, $S(=O)_2R^{b5}$, $NR^{c5}S(=O)_2R^{b5}$ and $S(=O)_2NR^{c5}R^{d5}$;

R^{15a} and R^{15b} are independently selected from H and C_{1-6} alkyl, wherein said alkyl of R^{15a} and R^{15b} is optionally substituted with 0, 1, 2, or 3 substituents selected from R^{20};

R^{16} is independently at each occurrence selected from halo, CN, OH, OR^{a6}, SR^{a6}, $C(=O)R^{b6}$, $C(=O)NR^{c6}R^{d6}$, $C(=O)OR^{a6}$, $OC(=O)R^{b6}$, $OC(=O)NR^{c6}R^{d6}$, $NR^{c6}R^{d6}$, $NR^{c6}C(=O)R^{b6}$, $NR^{c6}C(=O)NR^{c6}R^{d6}$, $NR^{c6}C(=O)OR^{a6}$, $S(=O)R^{b6}$, $S(=O)NR^{c6}R^{d6}$, $S(=O)_2R^{b6}$, $NR^{c6}S(=O)_2R^{b6}$ and $S(=O)_2NR^{c6}R^{d6}$, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^{16} are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^{17} and R^{18} are independently at each occurrence selected from halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^a, R^c, and R^d are independently at each occurrence selected from H and C_{1-6} alkyl;

R^b is at each occurrence C_{1-6} alkyl;

R^{a1}, R^{b1}, R^{c1} and R^{d1} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a1}, R^{b1}, R^{c1} and R^{d1} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a3}, R^{b3}, R^{c3} and R^{d3} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a3}, R^{b3}, R^{c3} and R^{d3} are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, OR^{a4}, SR^{a4}, $C(=O)R^{b4}$, $C(=O)NR^{c4}R^{d4}$, $C(=O)OR^{a4}$, $OC(=O)R^{b4}$, $OC(=O)NR^{c4}R^{d4}$, $NR^{c4}R^{d4}$, $NR^{c4}C(=O)R^{b4}$, $NR^{c4}C(=O)NR^{c4}R^{d4}$, $NR^{c4}C(=O)OR^{a4}$, $S(=O)R^{b4}$, $S(=O)NR^{c4}R^{d4}$, $S(=O)_2R^{b4}$, $NR^{c4}S(=O)_2R^{b4}$ and $S(=O)_2NR^{c4}R^{d4}$;

R^{a4}, R^{b4}, R^{c4} and R^{d4} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a4}, R^{b4}, R^{c4} and R^{d4} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a5}, R^{b5}, R^{c5} and R^{d5} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a5}, R^{b5}, R^{c5} and R^{d5} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a6}, R^{c6} and R^{d6} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a6}, R^{c6} and R^{d6} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

alternatively, R^{c6} and R^{d6} together with the nitrogen atom to which they are attached may be combined to form a 4-7 membered heterocycloalkyl group comprising carbon, nitrogen, and 0, 1, or 2 additional heteroatoms selected from N, O and S, wherein said 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{b6} is independently at each occurrence selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and 4-7 membered heterocycloalkyl group are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20}; and

R^{20} is at each occurrence independently selected from H, halo, OH, CN, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkyl-C(=O)-, C_{1-4} alkyl-C(=O)O-, C_{1-4} alkyl-OC(=O)-, HOC(=O)-, $H_2NC(=O)$-, C_{1-4} alkyl-NHC(=O)-, di(C_{1-4} alkyl)NC(=O)-, C_{1-4} alkyl-C(=O)NH-, C_{1-4} alkyl-S(=O)-, $H_2NS(=O)$-, C_{1-4} alkyl-NHS(=O)-, di(C_{1-4} alkyl)NS(=O)-, C_{1-4} alkyl-$S(=O)_2$-, C_{1-4} alkyl-$S(=O)_2NH$-, $H_2NS(=O)_2$-, C_{1-4} alkyl-$NHS(=O)_2$-, and di(C_{1-4} alkyl)$NS(=O)_2$-.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:

---- represents a single bond or a double bond;

L is CR^9R^{9a}, O, S, SO, or SO_2;

Cy^1 is selected from phenyl or a 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said phenyl or 5-6 membered heteroaryl of Cy^1 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{11};

R^1 is selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$,

$S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^1 and R^2 are optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$, $S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$;

R^2 is selected from H, halo, CN, OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkyl-O-, and

C_{1-6} haloalkyl-O-;

provided neither R^1 nor R^2 are Cl, Br, I, CN, or OH when L is O or S;

Cy^3 is selected from phenyl, C_{3-7} cycloalkyl, a 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said phenyl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Cy^3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; additionally, wherein a ring-forming nitrogen atom of said 5-10 membered heteroaryl group or a ring-forming nitrogen atom of said 4-10 membered heterocycloalkyl group is optionally oxidized;

R^4 is H or C_{1-6} alkyl;

R^5 is selected from =O and =S when C---N is a single bond,

alternatively, when C---N is a double bond then R^5 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $NR^{15a}R^{15b}$, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^5 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R^{15};

R^6 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said alkyl, alkenyl, and alkynyl of R^6 are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{16};

alternatively, R^6 is selected from C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3

heteroatoms selected from N, O and S, wherein said C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^6 are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^7 is selected from H, halo, CN, OR^a, NR^cR^d, SR^b, $C(=O)NR^cR^d$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and a 4-7 membered heterocycloalkyl group of R^7 are optionally substituted with 1, 2, or 3 groups independently selected from R^{17};

R^8 is selected from H, halo, CN, OH, C_{1-6} alkyl, C_{1-3} haloalkyl, and C_{1-6} alkyl-O-;

R^9 and R^{9a} are independently selected from H and C_{1-3} alkyl;

R^{11} is independently at each occurrence selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^{13} is independently at each occurrence selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{13} is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$;

R^{15} is independently at each occurrence selected from H, halo, CN, OH, OR^{a5}, SR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $OC(=O)R^{b5}$, $OC(=O)NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(=O)R^{b5}$, $NR^{c5}C(=O)NR^{c5}R^{d5}$, $NR^{c5}C(=O)OR^{a5}$, $S(=O)R^{b5}$, $S(=O)NR^{c5}R^{d5}$, $S(=O)_2R^{b5}$, $NR^{c5}S(=O)_2R^{b5}$ and $S(=O)_2NR^{c5}R^{d5}$;

R^{15a} and R^{15b} are independently selected from H and C_{1-6} alkyl, wherein said alkyl of R^{15a} and R^{15b} is optionally substituted with 0, 1, 2, or 3 substituents selected from R^{20};

R^{16} is independently at each occurrence selected from halo, CN, OH, OR^{a6}, SR^{a6}, $C(=O)R^{b6}$, $C(=O)NR^{c6}R^{d6}$, $C(=O)OR^{a6}$, $OC(=O)R^{b6}$, $OC(=O)NR^{c6}R^{d6}$, $NR^{c6}R^{d6}$, $NR^{c6}C(=O)R^{b6}$, $NR^{c6}C(=O)NR^{c6}R^{d6}$, $NR^{c6}C(=O)OR^{a6}$, $S(=O)R^{b6}$, $S(=O)NR^{c6}R^{d6}$, $S(=O)_2R^{b6}$, $NR^{c6}S(=O)_2R^{b6}$ and $S(=O)_2NR^{c6}R^{d6}$, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^{16} are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^{17} is independently at each occurrence selected from halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^a, R^c, and R^d are independently at each occurrence selected from H and C_{1-6} alkyl;

R^b is at each occurrence C_{1-6} alkyl;

R^{a1}, R^{b1}, R^{c1} and R^{d1} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a1}, R^{b1}, R^{c1} and R^{d1} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a3}, R^{b3}, R^{c3} and R^{d3} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a3}, R^{b3}, R^{c3} and R^{d3} are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, OR^{a4}, SR^{a4}, $C(=O)R^{b4}$, $C(=O)NR^{c4}R^{d4}$, $C(=O)OR^{a4}$, $OC(=O)R^{b4}$, $OC(=O)NR^{c4}R^{d4}$, $NR^{c4}R^{d4}$, $NR^{c4}C(=O)R^{b4}$, $NR^{c4}C(=O)NR^{c4}R^{d4}$, $NR^{c4}C(=O)OR^{a4}$, $S(=O)R^{b4}$, $S(=O)NR^{c4}R^{d4}$, $S(=O)_2R^{b4}$, $NR^{c4}S(=O)_2R^{b4}$ and $S(=O)_2NR^{c4}R^{d4}$;

R^{a4}, R^{b4}, R^{c4} and R^{d4} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a4}, R^{b4}, R^{c4} and R^{d4} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a5}, R^{b5}, R^{c5} and R^{d5} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a5}, R^{b5}, R^{c5} and R^{d5} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a6}, R^{c6} and R^{d6} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a6}, R^{c6} and R^{d6} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

alternatively, R^{c6} and R^{d6} together with the nitrogen atom to which they are attached may be combined to form a 4-7 membered heterocycloalkyl group comprising carbon, nitrogen, and 0, 1, or 2 additional heteroatoms selected from N, O and S, wherein said 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{b6} is independently at each occurrence selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and 4-7 membered heterocycloalkyl group are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20}; and

R^{20} is at each occurrence independently selected from H, halo, OH, CN, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkyl-C(=O)-, C_{1-4} alkyl-C(=O)O-, C_{1-4} alkyl-OC(=O)-, HOC(=O)-, $H_2NC(=O)$-, C_{1-4} alkyl-NHC(=O)-, di(C_{1-4} alkyl)NC(=O)-, C_{1-4} alkyl-C(=O)NH-, C_{1-4} alkyl-S(=O)-, $H_2NS(=O)$-, C_{1-4} alkyl-NHS(=O)-, di(C_{1-4} alkyl)NS(=O)-, C_{1-4} alkyl-$S(=O)_2$-, C_{1-4} alkyl-$S(=O)_2NH$-, $H_2NS(=O)_2$-, C_{1-4} alkyl-$NHS(=O)_2$-, and di(C_{1-4} alkyl)$NS(=O)_2$-.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:

---- represents a single bond or a double bond;

L is O;

Cy^1 is a five membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said five membered heteroaryl of Cy^1 is optionally substituted with 1, 2, or 3 groups independently selected from R^{11};

R^1 is selected from H, F, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$, $S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$, wherein said C_{1-6}

alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^1 and R^2 are optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a1}, SR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, $C(=O)OR^{a1}$, $OC(=O)R^{b1}$, $OC(=O)NR^{c1}R^{d1}$, $NR^{c1}R^{d1}$, $NR^{c1}C(=O)R^{b1}$, $NR^{c1}C(=O)NR^{c1}R^{d1}$, $NR^{c1}C(=O)OR^{a1}$, $S(=O)R^{b1}$, $S(=O)NR^{c1}R^{d1}$, $S(=O)_2R^{b1}$, $NR^{c1}S(=O)_2R^{b1}$ and $S(=O)_2NR^{c1}R^{d1}$;

R^2 is selected from H, F, and C_{1-6} alkyl;

Cy^3 is selected from phenyl, C_{3-7} cycloalkyl, a 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said phenyl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Cy^3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; additionally, wherein a ring-forming nitrogen atom of said 5-10 membered heteroaryl group or a ring-forming nitrogen atom of said 4-10 membered heterocycloalkyl group is optionally oxidized;

R^4 is H or C_{1-6} alkyl;

R^5 is selected from =O and =S when C---N is a single bond,

alternatively, when C---N is a double bond then R^5 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $NR^{15a}R^{15b}$, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^5 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R^{15};

R^6 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said alkyl, alkenyl, and alkynyl of R^6 are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{16};

R^7 is selected from H, halo, CN, OR^a, NR^cR^d, SR^b, $C(=O)NR^cR^d$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and a 4-7 membered heterocycloalkyl

group of R^7 are optionally substituted with 1, 2, or 3 groups independently selected from R^{17};

R^8 is selected from H, halo, CN, OH, C_{1-6} alkyl, C_{1-3} haloalkyl, and C_{1-6} alkyl-O-;

R^{11} is independently at each occurrence selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^{13} is independently at each occurrence selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{13} is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$;

R^{15} is independently at each occurrence selected from H, halo, CN, OH, OR^{a5}, SR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $OC(=O)R^{b5}$, $OC(=O)NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(=O)R^{b5}$, $NR^{c5}C(=O)NR^{c5}R^{d5}$, $NR^{c5}C(=O)OR^{a5}$, $S(=O)R^{b5}$, $S(=O)NR^{c5}R^{d5}$, $S(=O)_2R^{b5}$, $NR^{c5}S(=O)_2R^{b5}$ and $S(=O)_2NR^{c5}R^{d5}$;

R^{15a} and R^{15b} are independently selected from H and C_{1-6} alkyl, wherein said alkyl of R^{15a} and R^{15b} is optionally substituted with 0, 1, 2, or 3 substituents selected from R^{20};

R^{16} is independently at each occurrence selected from halo, CN, OH, OR^{a6}, SR^{a6}, $C(=O)R^{b6}$, $C(=O)NR^{c6}R^{d6}$, $C(=O)OR^{a6}$, $OC(=O)R^{b6}$, $OC(=O)NR^{c6}R^{d6}$, $NR^{c6}R^{d6}$, $NR^{c6}C(=O)R^{b6}$, $NR^{c6}C(=O)NR^{c6}R^{d6}$, $NR^{c6}C(=O)OR^{a6}$, $S(=O)R^{b6}$, $S(=O)NR^{c6}R^{d6}$, $S(=O)_2R^{b6}$, $NR^{c6}S(=O)_2R^{b6}$ and $S(=O)_2NR^{c6}R^{d6}$, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^{16} are each optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^{17} is independently at each occurrence selected from halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^a, R^c, and R^d are independently at each occurrence selected from H and C_{1-6} alkyl;

R^b is at each occurrence C_{1-6} alkyl;

R^{a1}, R^{b1}, R^{c1} and R^{d1} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a1}, R^{b1}, R^{c1} and R^{d1} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a3}, R^{b3}, R^{c3} and R^{d3} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a3}, R^{b3}, R^{c3} and R^{d3} are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, OR^{a4}, SR^{a4}, $C(=O)R^{b4}$, $C(=O)NR^{c4}R^{d4}$, $C(=O)OR^{a4}$, $OC(=O)R^{b4}$, $OC(=O)NR^{c4}R^{d4}$, $NR^{c4}R^{d4}$, $NR^{c4}C(=O)R^{b4}$, $NR^{c4}C(=O)NR^{c4}R^{d4}$, $NR^{c4}C(=O)OR^{a4}$, $S(=O)R^{b4}$, $S(=O)NR^{c4}R^{d4}$, $S(=O)_2R^{b4}$, $NR^{c4}S(=O)_2R^{b4}$ and $S(=O)_2NR^{c4}R^{d4}$;

R^{a4}, R^{b4}, R^{c4} and R^{d4} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a4}, R^{b4}, R^{c4} and R^{d4} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a5}, R^{b5}, R^{c5} and R^{d5} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a5}, R^{b5}, R^{c5} and R^{d5} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a6}, R^{c6} and R^{d6} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a6}, R^{c6} and R^{d6} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

alternatively, R^{c6} and R^{d6} together with the nitrogen atom to which they are attached may be combined to form a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{b6} is independently at each occurrence selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl group

comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl group, and 4-7 membered heterocycloalkyl group are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20}; and

R^{20} is at each occurrence independently selected from H, halo, OH, CN, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkyl-C(=O)-, C_{1-4} alkyl-C(=O)O-, C_{1-4} alkyl-OC(=O)-, HOC(=O)-, $H_2NC(=O)$-, C_{1-4} alkyl-NHC(=O)-, di(C_{1-4} alkyl)NC(=O)-, C_{1-4} alkyl-C(=O)NH-, C_{1-4} alkyl-S(=O)-, $H_2NS(=O)$-, C_{1-4} alkyl-NHS(=O)-, di(C_{1-4} alkyl)NS(=O)-, C_{1-4} alkyl-$S(=O)_2$-, C_{1-4} alkyl-$S(=O)_2NH$-, $H_2NS(=O)_2$-, C_{1-4} alkyl-$NHS(=O)_2$-, and di(C_{1-4} alkyl)$NS(=O)_2$-.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein:

---- represents a single bond or a double bond;

L is O;

Cy^1 is a five membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said five membered heteroaryl of Cy^1 is optionally substituted with 1, 2, or 3 groups independently selected from R^{11};

R^1 is selected from H, F, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a1}, $C(=O)R^{b1}$, $C(=O)NR^{c1}R^{d1}$, and $C(=O)OR^{a1}$;

R^2 is selected from H, F, and C_{1-6} alkyl;

Cy^3 is selected from phenyl, C_{3-7} cycloalkyl, a 5-10 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said phenyl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl of Cy^3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; additionally, wherein a ring-forming nitrogen atom of said 5-10 membered heteroaryl group or a ring-forming nitrogen atom of said 4-10 membered heterocycloalkyl group is optionally oxidized;

R^4 is H or C_{1-6} alkyl;

R^5 is selected from =O and =S when C----N is a single bond,

alternatively, when C----N is a double bond then R^5 is selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $NR^{15a}R^{15b}$, phenyl, C_{3-7} cycloalkyl, 5-

6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^5 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R^{15};

R^6 is selected from H and C_{1-6} alkyl, wherein said alkyl of R^6 is optionally substituted by 1, 2, or 3 groups independently selected R^{16};

R^7 is selected from H, halo, CN, C_{1-6} alkyl, C_{1-6} alkoxy, phenyl, and 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, wherein said alkyl, phenyl, or 5-6 membered heteroaryl group, of R^7 are optionally substituted with 1, 2, or 3 groups independently selected from R^{17};

R^8 is selected from H, halo, CN, OH, and C_{1-6} alkyl;

R^{11} is independently at each occurrence selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^{13} is independently at each occurrence selected from H, halo, CN, OH, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl of R^{13} is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, OR^{a3}, SR^{a3}, $C(=O)R^{b3}$, $C(=O)NR^{c3}R^{d3}$, $C(=O)OR^{a3}$, $OC(=O)R^{b3}$, $OC(=O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(=O)R^{b3}$, $NR^{c3}C(=O)NR^{c3}R^{d3}$, $NR^{c3}C(=O)OR^{a3}$, $S(=O)R^{b3}$, $S(=O)NR^{c3}R^{d3}$, $S(=O)_2R^{b3}$, $NR^{c3}S(=O)_2R^{b3}$ and $S(=O)_2NR^{c3}R^{d3}$;

R^{15} is independently at each occurrence selected from H, halo, CN, OH, OR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $NR^{c5}R^{d5}$, and $NR^{c5}C(=O)R^{b5}$;

R^{15a} and R^{15b} are independently selected from H and C_{1-6} alkyl, wherein said alkyl of R^{15a} and R^{15b} is optionally substituted with 0, 1, 2, or 3 substituents selected from R^{20};

R^{16} is independently at each occurrence selected from halo, CN, OH, OR^{a6}, $C(=O)R^{b6}$, $C(=O)NR^{c6}R^{d6}$, $C(=O)OR^{a6}$, $OC(=O)R^{b6}$, $NR^{c6}R^{d6}$, $NR^{c6}C(=O)R^{b6}$, and a 4-7 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said 4-7 membered heterocycloalkyl of R^{16} is optionally substituted by 1, 2, 3, or 4 groups independently selected R^{20};

R^{17} is independently at each occurrence selected from halo, CN, OR^a, NR^cR^d, SR^b, and $C(=O)NR^cR^d$;

R^a, R^c, and R^d are independently at each occurrence selected from H and C_{1-6} alkyl;

R^b is at each occurrence C_{1-6} alkyl;

R^{a1}, R^{b1}, R^{c1} and R^{d1} are independently at each occurrence selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{1-6} haloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a1}, R^{b1}, R^{c1} and R^{d1} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a3}, R^{b3}, R^{c3} and R^{d3} are independently at each occurrence selected from H and C_{1-6} alkyl, wherein said C_{1-6} alkyl forming R^{a3}, R^{b3}, R^{c3} and R^{d3} is optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, OR^{a4}, SR^{a4}, $C(=O)R^{b4}$, $C(=O)NR^{c4}R^{d4}$, $C(=O)OR^{a4}$, $OC(=O)R^{b4}$, $OC(=O)NR^{c4}R^{d4}$, $NR^{c4}R^{d4}$, $NR^{c4}C(=O)R^{b4}$, $NR^{c4}C(=O)NR^{c4}R^{d4}$, $NR^{c4}C(=O)OR^{a4}$, $S(=O)R^{b4}$, $S(=O)NR^{c4}R^{d4}$, $S(=O)_2R^{b4}$, $NR^{c4}S(=O)_2R^{b4}$ and $S(=O)_2NR^{c4}R^{d4}$;

R^{a4}, R^{b4}, R^{c4} and R^{d4} are independently at each occurrence selected from H and C_{1-6} alkyl, wherein said C_{1-6} alkyl forming R^{a4}, R^{b4}, R^{c4} and R^{d4} is optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a5}, R^{b5}, R^{c5} and R^{d5} are independently at each occurrence selected from H and C_{1-6} alkyl, wherein said C_{1-6} alkyl forming R^{a5}, R^{b5}, R^{c5} and R^{d5} is optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{a6}, R^{c6} and R^{d6} are independently at each occurrence selected from H and C_{1-6} alkyl;


alternatively, R^{c6} and R^{d6} together with the nitrogen atom to which they are attached may be combined to form a 4-7 membered heterocycloalkyl group comprising carbon, nitrogen, and 0, 1, or 2 additional heteroatoms selected from N, O and S, wherein said 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, or 3 substituents independently selected from R^{20};

R^{b6} is independently at each occurrence selected from C_{1-6} alkyl; and

R^{20} is at each occurrence independently selected from H, halo, OH, CN, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} alkyl-C(=O)-, C_{1-4} alkyl-C(=O)O-, C_{1-4} alkyl-OC(=O)-, HOC(=O)-, $H_2NC(=O)$-, C_{1-4} alkyl-NHC(=O)-, di(C_{1-4} alkyl)NC(=O)-, C_{1-4} alkyl-

C(=O)NH-, C_{1-4} alkyl-S(=O)-, $H_2NS(=O)$-, C_{1-4} alkyl-NHS(=O)-, di(C_{1-4} alkyl)NS(=O)-, C_{1-4} alkyl-$S(=O)_2$-, C_{1-4} alkyl-$S(=O)_2NH$-, $H_2NS(=O)_2$-, C_{1-4} alkyl-$NHS(=O)_2$-, and di(C_{1-4} alkyl)$NS(=O)_2$-.

6. The compound of claim 1 or 2 having Formula (**Ia**):



(**Ia**)

or a pharmaceutically acceptable salt thereof, wherein:

represents a single bond or a double bond;

Cy^1 is selected from isoxazolyl and pyrazolyl, wherein said isoxazolyl and pyrazolyl of Cy^1 is optionally substituted with 1 or 2 groups independently selected from R^{11};

R^1 is selected from H, methyl, $-C(=O)OCH_2CH_3$, $-C(=O)N(H)CH_2CH_3$, $-C(=O)N(H)CH_2CH_2OH$, and $-C(=O)N(CH_3)_2$;

Cy^3 is selected from phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl and tetrahydrofuranyl, wherein said phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl and tetrahydrofuranyl of Cy^3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13};

R^5 is =O when C N is a single bond,

alternatively, when C N is a double bond then R^5 is H, methyl, $-CH=CH_2$, $-N(H)CH_3$, $-N(H)CH_2CH_3$, $-N(H)CH(CH_3)_2$, $-N(CH_3)_2$, $-N(H)CH_2CH_2OH$, $-N(H)CH(CH_3)CH_2OH$, $-N(H)CH_2CH(OH)CH_3$, $-N(H)C(CH_3)_2CH_2OH$, $-N(CH_3)CH_2CH_2OH$, morpholinyl, pyrrolidinyl, hydroxypyrrolidinyl, piperidinyl, hydroxypiperidinyl, azetidinyl, hydroxyazetidinyl, piperazinyl, butoxycarbonylpiperazinyl, and phenyl;

R^6 is selected from H, methyl, ethyl, and propyl wherein said methyl, ethyl, and propyl of R^6 are each optionally substituted by 1, 2, or 3 groups independently selected R^{16};

R^7 is selected from H, F, Cl, Br, methyl, methoxy, ethoxy, CN, phenyl, and pyridinyl;

R^{11} is independently at each occurrence selected from H, methyl, ethyl, chloro, and methoxy;

R^{13} is independently at each occurrence selected from H, F, CN, methoxy, $-CF_3$, $-OCH_2C(=O)OH$, $-OCH_2C(=O)N(H)CH_2CH_3$, $-OCH_2C(=O)N(H)CH_2CH_2OH$, and $-OCH_2C(=O)N(CH_3)_2$; and

R^{16} is independently at each occurrence selected from morpholinyl, and piperidinyl.

7. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:-

a) L is O; or

b) L is S; or

c) L is CH_2 .

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Cy^1 is isoxazolyl substituted with 1 or 2 groups independently selected from R^{11}.

9. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Cy^1 is pyrazolyl substituted with 1 or 2 groups independently selected from R^{11}.

10. The compound of any one of claims 1 to 5 and 7 to 9, or a pharmaceutically acceptable salt thereof, wherein:-

a) R^1 is H; or

b) R^1 is methyl; or

c) R^1 is $-C(=O)OCH_2CH_3$; or

d) R^1 is $C(=O)N(H)CH_2CH_3$; or

e) R^1 is $C(=O)N(H)CH_2CH_2OH$; or

f) R^1 is $-C(=O)N(CH_3)_2$; or

g) R^1 is $-C(=O)N(H)CH_3$; or

h) R^1 is $-C(=O)NH_2$; or

i) R^1 is $-CH_2OH$.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein:

a) R^2 is H; or

b) R^2 is methyl.

12. The compound of any one of claims 1 to 5 and 7 to 11, or a pharmaceutically acceptable salt thereof, wherein:-

a) Cy^3 is phenyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; or

b) Cy^3 is pyridinyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; or

c) Cy^3 is oxidopyridinyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; or

d) Cy^3 is thiazolyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; or

e) Cy^3 is cyclohexyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; or

f) Cy^3 is dihydrobenzofuranyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; or

g) Cy^3 is tetrahydrofuranyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}; or

h) Cy^3 is piperidinyl optionally substituted with 1, 2, 3, or 4 groups independently selected from R^{13}.

13. The compound of any one of claims 1 and 7 to 12, or a pharmaceutically acceptable salt thereof, wherein R^4 is H, -C(=O)NH_2, -CH_2NH_2, -$CH_2N(H)C(=O)CH_3$, -C(=O)N(H)CH_3, -CH_2CH_3, or -CH_3.

14. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R^4 is H.

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is =O when C---N is a single bond.

16. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^5 is =S when C---N is a single bond.

17. The compound of any one of claims 1 and 7 to 14, or a pharmaceutically acceptable salt thereof, wherein when C---N is a double bond then R^5 is selected from H, C_{1-4} alkyl, -CH=CH_2, $NR^{15a}R^{15b}$, -C(=O)$NR^{15a}R^{15b}$, phenyl, and a 4-10 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, and 4-10 membered heterocycloalkyl of R^5 is optionally substituted by 1 or 2 groups independently selected from R^{15}.

18. The compound of any one of claims 1 and 7 to 14, or a pharmaceutically acceptable salt thereof, wherein when C---N is a double bond then R^5 is selected from H, C_{1-4} alkyl, -CH=CH_2, $NR^{15a}R^{15b}$, -C(=O)$NR^{15a}R^{15b}$, phenyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,5-dihydro-1H-pyrrolyl, 1,4-diazepanyl, morpholinyl, and octahydropyrrolo[1,2-a]pyrazinyl, wherein said C_{1-4} alkyl, phenyl, azetidinyl, pyrolidinyl, piperidinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, 2,5-dihydro-1H-pyrrolyl, 1,4-diazepanyl, morpholinyl, and octahydropyrrolo[1,2-a]pyrazinyl of R^5 is optionally substituted by 1 or 2 groups independently selected from R^{15}.

19. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein when C---N is a double bond then R^5 is H, methyl, -CH=CH_2, -N(H)CH_3, -N(H)CH_2CH_3, -N(H)$CH(CH_3)_2$, -N$(CH_3)_2$, -N(H)CH_2CH_2OH, -N(H)$CH(CH_3)CH_2OH$, -N(H)$CH_2CH(OH)CH_3$, -N(H)$C(CH_3)_2CH_2OH$, -N$(CH_3)CH_2CH_2OH$, morpholinyl, pyrrolidinyl, hydroxypyrrolidinyl, piperidinyl,

hydroxypiperidinyl, azetidinyl, hydroxyazetidinyl, piperazinyl, butoxycarbonylpiperazinyl or phenyl.

20. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein when C---N is a double bond then R^5 is selected from a 4-6 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said 4-6 membered heterocycloalkyl of R^5 is optionally substituted by 1 or 2 groups independently selected from R^{15}.

21. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein:-

a) when C---N is a double bond then R^5 is pyrrolidinyl, wherein said pyrrolidinyl of R^5 is optionally substituted by 1 or 2 groups independently selected from R^{15}; or

b) when C---N is a double bond then R^5 is piperidinyl, wherein said piperidinyl of R^5 is optionally substituted by 1 or 2 groups independently selected from R^{15}; or

c) when C---N is a double bond then R^5 is azetidinyl, wherein said azetidinyl of R^5 is optionally substituted by 1 or 2 groups independently selected from R^{15}; or

d) when C---N is a double bond then R^5 is piperazinyl, wherein said piperazinyl of R^5 is optionally substituted by 1 or 2 groups independently selected from R^{15}.

22. The compound of any one of claims 1 and 7 to 21, or a pharmaceutically acceptable salt thereof, wherein R^{15} is independently at each occurrence selected from C_{1-6} alkyl, CN, OR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(=O)R^{b5}$, $NR^{c5}C(=O)NR^{c5}R^{d5}$, $NR^{c5}C(=O)OR^{a5}$, $S(=O)_2R^{b5}$, $NR^{c5}S(=O)_2R^{b5}$, and $S(=O)_2NR^{c5}R^{d5}$, wherein said C_{1-6} alkyl, is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR^{a5}, SR^{a5}, $C(=O)R^{b5}$, $C(=O)NR^{c5}R^{d5}$, $C(=O)OR^{a5}$, $OC(=O)R^{b5}$, $OC(=O)NR^{c5}R^{d5}$, $NR^{c5}R^{d5}$, $NR^{c5}C(=O)R^{b5}$, $NR^{c5}C(=O)NR^{c5}R^{d5}$, $NR^{c5}C(=O)OR^{a5}$, $S(=O)R^{b5}$, $S(=O)NR^{c5}R^{d5}$, $S(=O)_2R^{b5}$, $NR^{c5}S(=O)_2R^{b5}$, $S(=O)_2NR^{c5}R^{d5}$, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl, and C_{3-7} cycloalkyl.

23. The compound of any one of claims 1 and 7 to 22, or a pharmaceutically acceptable salt thereof, wherein R^6 is H, C_{1-4} alkyl, or C_{1-4} alkoxy.

24. The compound of any one of claims 1 and 7 to 22, or a pharmaceutically acceptable salt thereof, wherein R^6 is H.

25. The compound of any one of claims 1 to 4 and 7 to 24, or a pharmaceutically acceptable salt thereof, wherein R^7 is selected from H, halo, CN, NR^cR^d, C_{1-6} alkyl, C_{2-6} alkenyl, 5-6 membered heteroaryl group comprising carbon and 1, 2, 3 or 4 heteroatoms selected from N, O and S, and a 5-6 membered heterocycloalkyl group comprising carbon and 1, 2, or 3 heteroatoms selected from N, O and S, wherein said alkyl, alkenyl, 5-6 membered heteroaryl group, and 5-6 membered heterocycloalkyl group of R^7 are optionally substituted with 1, 2, or 3 groups independently selected from R^{17}.

26. The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein:-

a) R^7 is H; or

b) R^7 is Br; or


c) R^7 is methyl; or

d) R^7 is CN.

27. The compound of any one of claims 1 to 5 and 7 to 26, or a pharmaceutically acceptable salt thereof, wherein R^8 is selected from H, halo, C_{1-4} alkyl, and CN.


28. The compound of any one of claims 1 to 5 and 7 to 26, or a pharmaceutically acceptable salt thereof, wherein R^8 is H.

29. The compound of any one of claims 1 to 5, 7 to 15 and 23 to 28, or a pharmaceutically acceptable salt thereof, having Formula (IIa):




(IIa).

30. The compound of any one of claims 1-6, 9-10, 12, and 23-26, or a pharmaceutically acceptable salt thereof, having Formula (IIIa):




(IIIa).

31. The compound of any one of claims 1-6, 12, 23, and 24, or a pharmaceutically acceptable salt thereof, having Formula (IVa):




(IVa).

32. The compound of any one of claims 1 to 5, 7 to 14 and 17 to 28, or a pharmaceutically acceptable salt thereof, having Formula (IIb):




(IIb).

33. The compound of any one of claims 1-6, 9-10, 12, 15-22, 25, and 26, or a pharmaceutically acceptable salt thereof, having Formula (IIIb):



(IIIb).

34. The compound of any one of claims 1-6, 12, and 15-21, or a pharmaceutically acceptable salt thereof, having Formula (IVb):



(IVb).

35. The compound of claim 1:

a) selected from:

7-(3,5-dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

(4*R*)-7-(3,5-dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

(4*S*)-7-(3,5-dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-1-methyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-5-methyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

4-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazin-4-yl]benzonitrile;

7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-(3-methoxyphenyl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-(2-methoxyphenyl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-(2,4-difluorophenyl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-2-methyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazine;

7-(3,5-dimethylisoxazol-4-yl)-1-(2-morpholin-4-ylethyl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethyl-*1H*-pyrazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3-methyl-*1H*-pyrazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

(4*R*)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

(4*S*)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-(1-oxidopyridin-2-yl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

4-cyclohexyl-7-(3,5-dimethylisoxazol-4-yl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-(tetrahydrofuran-2-yl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-(5-fluoropyridin-2-yl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

Ethyl 7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-5-carboxylate;

7-(3,5-dimethylisoxazol-4-yl)-4-(1,3-thiazol-2-yl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

2-{2-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazin-4-yl]phenoxy}-*N*-ethylacetamide;

ethyl7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-phenyl-1,2,4,5-

tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-5-carboxylate;

7-(3,5-dimethylisoxazol-4-yl)-*N*-ethyl-2-oxo-4-phenyl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-5-carboxamide;

7-(3,5-Dimethylisoxazol-4-yl)-*N*-isopropyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-amine;

7-(3,5-Dimethylisoxazol-4-yl)-*N*-methyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-amine;

7-(3,5-Dimethylisoxazol-4-yl)-*N*-ethyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-amine;

7-(3,5-Dimethylisoxazol-4-yl)-*N*,*N*-dimethyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-amine;

2-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]amino}ethanol;

2-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]amino}propan-1-ol;

1-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]amino}propan-2-ol;

2-{[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]amino}-2-methylpropan-1-ol;

2-[[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl](methyl)amino]ethanol;

7-(1-Methyl-*1H*-pyrazol-5-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

9-Bromo-7-(1-methyl-*1H*-pyrazol-5-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one*;*

9-Methyl-7-(1-methyl-*1H*-pyrazol-5-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(4-Chloro-1-methyl-*1H*-pyrazol-5-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazine;

7-(3,5-dimethylisoxazol-4-yl)-4-phenyl-2-piperazin-1-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazine;

7-(3,5-dimethylisoxazol-4-yl)-2,4-diphenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazine;

7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-phenyl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-9-carbonitrile;

7-(3,5-Dimethylisoxazol-4-yl)-4,9-diphenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(1,4-dimethyl-*1H*-pyrazol-5-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

9-Bromo-7-(3,5-dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-9-methyl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-*N*,*N*-dimethyl-2-oxo-4-phenyl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-5-carboxamide;

7-(3,5-Dimethylisoxazol-4-yl)-*N*-(2-hydroxyethyl)-2-oxo-4-phenyl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-5-carboxamide;

7-(3,5-Dimethylisoxazol-4-yl)-4-(4-fluorophenyl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

2-{2-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazin-4-yl]phenoxy}-N-(2-hydroxyethyl)acetamide;

2-{2-[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazin-4-yl]phenoxy}-N,N-dimethylacetamide;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-9-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-2-morpholin-4-yl-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazine;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-2-pyrrolidin-1-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazine;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-2-piperidin-1-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazine;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]piperidin-4-ol;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]piperidin-3-ol;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]azetidin-3-ol; and

4-[7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2-yl]piperazine-1-carboxylate;

or a pharmaceutically acceptable salt thereof; or

b) selected from:

7-(3,5-Dimethylisoxazol-4-yl)-5,5-dimethyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(1*H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-5-(hydroxymethyl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(1*H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-4-piperidin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(1*H*)-one;

4-(1-Acetylpiperidin-2-yl)-7-(3,5-dimethylisoxazol-4-yl)-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(1*H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-4-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-Dimethylisoxazol-4-yl)-4-ethyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(1*H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-N-methyl-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-4-carboxamide;

N-{[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazin-4-yl]methyl}acetamide;

4-(Aminomethyl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(1*H*)-one;

7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-*de*][1,4]benzoxazine-4-carboxamide;

7-(3,5-dimethylisoxazol-4-yl)-5-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-dimethylisoxazol-4-yl)-N-methyl-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazine-5-carboxamide;

7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazine-5-carboxamide;

7-(3,5-dimethylisoxazol-4-yl)-4-(5-fluoropyridin-3-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-dimethylisoxazol-4-yl)-4-[1-(methylsulfonyl)piperidin-2-yl]-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

2-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]-N-isopropylpiperidine-1-carboxamide;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-9-(1-methyl-1H-pyrazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

5-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]-N,N-dimethylpyridine-2-carboxamide;

tert-butyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]-3,6-dihydropyridine-1(2H)-carboxylate;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-9-pyrimidin-5-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-9-(1-methyl-1H-pyrazol-5-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

ethyl (2E)-3-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]acrylate;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-9-(1,2,3,6-tetrahydropyridin-4-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-vinyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(1R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]ethane-1,2-diol;

1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]ethanol;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-N,N-dimethyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxamide;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

tert-Butyl (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxylate;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-(morpholin-4-ylcarbonyl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-N-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxamide;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2-carboxamide;

tert-Butyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3,6-dihydropyridine-1(2H)-carboxylate;

tert-Butyl 3-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-2,5-dihydro-1H-pyrrole-1-carboxylate;

tert-Butyl 5-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3,6-dihydropyridine-1(2H)-carboxylate;

tert-Butyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-1-carboxylate;

tert-Butyl 3-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidine-1-carboxylate;

tert-Butyl 3-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-1-carboxylate;

(4S)-2-(1-Acetylpiperidin-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-(1,2,3,6-tetrahydropyridin-4-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(2,5-dihydro-1H-pyrrol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-pyrrolidin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-(1,2,5,6-tetrahydropyridin-3-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-piperidin-3-yl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-Acetylpiperidin-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-[1-(cyclopropylcarbonyl)piperidin-4-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[1-(methylsulfonyl)piperidin-4-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetylpyrrolidin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-[1-(cyclopropylcarbonyl)pyrrolidin-3-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[1-(methylsulfonyl)pyrrolidin-3-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetyl-1,2,5,6-tetrahydropyridin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(1-acetylpiperidin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-[1-(cyclopropylcarbonyl)piperidin-3-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[1-(methylsulfonyl)piperidin-3-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

7-(3,5-Dimethylisoxazol-4-yl)-4-phenyl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one;

7-(3,5-Dimethylisoxazol-4-yl)-1-methyl-4-phenyl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one;

7-(3,5-Dimethylisoxazol-4-yl)-1-methoxy-4-pyridin-2-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one;

7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one;

7-[5-(Hydroxymethyl)-3-methylisoxazol-4-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-[5-(Fluoromethyl)-3-methylisoxazol-4-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

3-[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]pyridine-2-carbonitrile;

3-[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]pyridine-2-carboxamide;

3-[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]-N-methylpyridine-2-carboxamide;

3-[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]-N,N-dimethylpyridine-2-carboxamide;

4-[2-(Aminomethyl)pyridin-3-yl]-7-(3,5-dimethylisoxazol-4-yl)-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

N-({3-[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]pyridin-2-yl}methyl)acetamide;

Methyl 3-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]pyridine-2-carboxylate;

3-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]-N-ethylpyridine-2-carboxamide;

N-Cyclopropyl-3-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]pyridine-2-carboxamide;

3-[7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]-N-(2-hydroxyethyl)pyridine-2-carboxamide;

3-[7-(3,5-dimethylisoxazol-4-yl)-2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl]-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide;

(4S)-9-(Aminomethyl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

N-{[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]methyl}acetamide;

N-{[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]methyl}-2-phenylacetamide;

N-{[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]methyl}-2-methoxyacetamide;

N-{[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]methyl}methanesulfonamide;

N-{[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]methyl}-N'-isopropylurea;

2-(Dimethylamino)-N-{[(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-9-yl]methyl}acetamide;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-9-(1-hydroxyethyl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

(3R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-isopropylpyrrolidine-3-carboxamide;

1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3-methylpyrrolidin-3-ol;

4-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-1,4-diazepane-1-sulfonamide;

(4S)-2-(4-Acetyl-1,4-diazepan-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-[4-(methylsulfonyl)-1,4-diazepan-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-Dimethylisoxazol-4-yl)-2-piperazin-1-yl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

2-{4-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazin-1-yl}-N,N-dimethylacetamide;

2-Cyano-N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N-methylacetamide;

N-{(3R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}morpholine-4-carboxamide;

7-(3,5-Dimethylisoxazol-4-yl)-2-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

Methyl {(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}carbamate;

7-(3,5-Dimethylisoxazol-4-yl)-9-fluoro-N,N-dimethyl-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

1-[7-(3,5-Dimethylisoxazol-4-yl)-9-fluoro-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

7-(3,5-Dimethylisoxazol-4-yl)-N-ethyl-9-fluoro-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

(3R)-1-[7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

1-[7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-ol;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-morpholin-4-yl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-2-pyrrolidin-1-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-methylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-azetidin-1-yl-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-ol;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-1-methylpiperazin-2-one;

ethyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazine-1-carboxylate;

(3R)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

(3S)-1-[(4S)-7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-ol;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-ol;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-3-ol;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-3-ol;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N,N-dimethylpiperidin-4-amine;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazin-2-one;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(methylsulfonyl)piperazin-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-isopropylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-4-carbonitrile;

{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}methanol;

2-{4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazin-1-yl}ethanol;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-phenylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-2-(4-benzylpiperazin-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N,N-dimethylpyrrolidin-3-amine;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N,N-dimethylpyrrolidin-3-amine;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpyrrolidin-3-amine;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpyrrolidin-3-amine;

tert-butyl {(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}carbamate;

tert-butyl {(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}carbamate;

(4S)-2-[4-(cyclopropylmethyl)piperazin-1-yl]-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(2-methoxyethyl)piperazin-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

2-[[7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl](methyl)amino]ethanol;

7-(3,5-dimethylisoxazol-4-yl)-N-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

7-(3,5-dimethylisoxazol-4-yl)-N,N-dimethyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-amine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidine-4-carboxamide;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpiperidine-4-carboxamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}acetamide;

2-{4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazin-1-yl}acetamide;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-ethylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-4-methylpiperidin-4-ol;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-3-methylpiperazin-2-one;

tert-butyl {1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}carbamate;

tert-butyl 4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-1,4-diazepane-1-carboxylate;

2-{[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino}ethanol;

tert-butyl (2-{[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]amino}ethyl)carbamate;

N-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]ethane-1,2-diamine;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}acetamide;

N-{(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}acetamide;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-amine;

(3S)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-amine;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2,2,2-trifluoroacetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2-methoxyacetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}cyclopropanecarboxamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}methanesulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}propanamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2-methylpropanamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}cyclobutanecarboxamide;

2-cyano-N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}acetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}tetrahydro-2H-pyran-4-carboxamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}ethanesulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}propane-1-sulfonamide;

N'-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N,N-dimethylurea;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}propane-2-sulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}cyclopropanesulfonamide;

methyl {(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}methylcarbamate;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N-methylmethanesulfonamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-2-methoxy-N-methylacetamide;

N-{(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidin-3-yl}-N-methylacetamide;

(4S)-2-(4-acetylpiperazin-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-propionylpiperazin-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(ethylsulfonyl)piperazin-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

4-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperazine-1-sulfonamide;

1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-amine;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}acetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}propanamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}-2-methylpropanamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}-2-methoxyacetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}cyclopropanecarboxamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}cyclobutanecarboxamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}methanesulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}ethanesulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]azetidin-3-yl}propane-2-sulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}methanesulfonamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}-2-methoxyacetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}-2,2,2-trifluoroacetamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}propanamide;

N-{1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]piperidin-4-yl}propanamide;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-(4-propionyl-1,4-diazepan-1-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-2-[4-(ethylsulfonyl)-1,4-diazepan-1-yl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-methylpyrrolidine-3-carboxamide;

(3R)-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]-N-ethylpyrrolidine-3-carboxamide;

(3R)-N-cyclopropyl-1-[(4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl]pyrrolidine-3-carboxamide;

(4S)-8,9-dichloro-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-Dimethylisoxazol-4-yl)-9-[(isopropylamino)methyl]-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-Dimethylisoxazol-4-yl)-9-(hydroxymethyl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine-2(1H)-thione;

7-(3,5-dimethylisoxazol-4-yl)-9-(1H-pyrazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-dimethylisoxazol-4-yl)-9-(3-methyl-1H-pyrazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-dimethylisoxazol-4-yl)-9-(3,5-dimethyl-1H-pyrazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-9-(6-hydroxypyridin-3-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-9-(2-hydroxypyridin-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

(4S)-7-(3,5-dimethylisoxazol-4-yl)-9-(2-hydroxypyridin-3-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

9-(anilinomethyl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-dimethylisoxazol-4-yl)-9-(1-hydroxy-2-methylpropyl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-dimethylisoxazol-4-yl)-9-fluoro-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

9-chloro-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;


9-bromo-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one;

7-(3,5-dimethylisoxazol-4-yl)-9-methyl-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one; and

7-(3,5-dimethylisoxazol-4-yl)-2-oxo-4-pyridin-2-yl-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazine-9-carbonitrile;

or a pharmaceutically acceptable salt thereof.

36. The compound of claim 1 which is a compound having the structure:




or a pharmaceutically acceptable salt thereof.

37. The compound of claim 1 which is (4*S*)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one, or a pharmaceutically acceptable salt thereof.

38. The compound of claim 1 which is (4*R*)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one, or a pharmaceutically acceptable salt thereof.

39. The compound of claim 36 which is



.

40. The compound of claim 37 which is (4*S*)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one.

41. The compound of claim 38 which is (4*R*)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one.

42. The compound of claim 1 which is (4S)-2-(4-acetylpiperazin-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine or a pharmaceutically acceptable salt thereof.

43. The compound of claim 42 which is (4S)-2-(4-acetylpiperazin-1-yl)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine.

44. The compound of claim 1 which is 7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-*de*][1,4]benzoxazin-2(*1H*)-one, or a pharmaceutically acceptable salt thereof.

45. The compound of claim 44 which is 7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-3-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one.

46. A pharmaceutical composition comprising a compound of any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

47. A method of inhibiting a BET protein *in vitro* comprising contacting a compound of any one of claims 1 to 38, 42, and 44, or a pharmaceutically acceptable salt thereof, with said BET protein.

48. A compound of any one of claims 1 to 38, 42, and 44, or a pharmaceutically acceptable salt thereof, for use in the treatment of:

(a) a proliferative disorder; or

(b) an autoimmune or inflammatory disease; or

(c) a viral infection.

49. A compound of any one of claims 1 to 38, 42, and 44,or a pharmaceutically acceptable salt thereof, for use in the treatment of:

a) a proliferative disorder wherein the proliferative disorder is cancer; or

b) an autoimmune or inflammatory disease, wherein the autoimmune or inflammatory disease is selected from allergy, allergic rhinitis, arthritis, asthma, chronic obstructive pulmonary disease, degenerative joint disease, dermatitis, organ rejection, eczema, hepatitis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, psoriasis, sepsis, sepsis syndrome, septic shock, systemic lupus erythematosus, tissue graft rejection, type I diabetes; or

c) a viral infection, wherein the viral infection is infection with adenovirus, Epstein-Barr virus, hepatitis B virus, hepatitis C virus, a herpes virus, human immunodeficiency virus, human papilloma virus or a pox virus.

50. The compound for use according to claim 49 for the treatment of a proliferative disorder, wherein:-

a)the proliferative disorder is cancer, wherein the cancer is adenocarcinoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell leukemia, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor; or

b) the proliferative disorder is a non-cancerous proliferative disorder.

51. Use of a compound of any one of claims 1 to 38, 42, and 44, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of:

(a) a proliferative disorder; or

(b) an autoimmune or inflammatory disease; or

(c) a viral infection.

52. Use of a compound of any one of claims 1 to 38, 42, and 44, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of:

a) a proliferative disorder wherein the proliferative disorder is cancer; or

b) an autoimmune or inflammatory disease, wherein the autoimmune or inflammatory disease is selected from allergy, allergic rhinitis, arthritis, asthma, chronic obstructive pulmonary disease, degenerative joint disease, dermatitis, organ rejection, eczema, hepatitis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, psoriasis, sepsis, sepsis syndrome, septic shock, systemic lupus erythematosus, tissue graft rejection, type I diabetes; or

c) a viral infection, wherein the viral infection is infection with adenovirus, Epstein-Barr virus, hepatitis B virus, hepatitis C virus, a herpes virus, human immunodeficiency virus, human papilloma virus or a pox virus.

53. The use according to claim 52 for the treatment of a proliferative disorder, wherein:

a) the proliferative disorder is cancer, wherein the cancer is adenocarcinoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, ocular cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, stomach cancer, T-cell leukemia, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, urogenital cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor; or

b) the proliferative disorder is a non-cancerous proliferative disorder.